Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
Sana Biotechnology (NASDAQ: SANA) announced a strategic shift to focus on type 1 diabetes and B-cell mediated autoimmune diseases. The company will suspend development of SC291 in oncology and SC379 glial progenitor cell program, seeking partnerships for these initiatives. The restructuring extends cash runway into 2026, though 2024 operating cash burn may exceed previous $200 million guidance.
The company will prioritize development of UP421 (HIP-modified islet cells), SC291 (for autoimmune diseases), SC262 (for refractory B-cell malignancies), and the fusogen platform. Clinical proof of concept data is expected across multiple studies in 2024 and 2025.
Sana Biotechnology (NASDAQ: SANA) ha annunciato un cambiamento strategico per concentrarsi su diabete di tipo 1 e malattie autoimmuni mediate dalle cellule B. L'azienda sospenderà lo sviluppo di SC291 in oncologia e del programma di cellule progenitrici gliali SC379, cercando partnership per queste iniziative. La ristrutturazione estenderà la liquidità disponibile fino al 2026, anche se il burn cash operativo del 2024 potrebbe superare la precedente stima di 200 milioni di dollari.
L'azienda darà priorità allo sviluppo di UP421 (cellule di isole modificate HIP), SC291 (per le malattie autoimmuni), SC262 (per le neoplasie B-cellulari refrattarie) e la piattaforma fusogena. I dati clinici di prova di concetto sono attesi in diversi studi nel 2024 e nel 2025.
Sana Biotechnology (NASDAQ: SANA) anunció un cambio estratégico para centrarse en diabetes tipo 1 y enfermedades autoinmunes mediadas por células B. La empresa suspenderá el desarrollo de SC291 en oncología y el programa de células progenitoras gliales SC379, buscando asociaciones para estas iniciativas. La reestructuración extenderá el flujo de efectivo hasta 2026, aunque la quema de efectivo operativo de 2024 podría superar la guía previa de 200 millones de dólares.
La empresa priorizará el desarrollo de UP421 (células de islotes modificadas HIP), SC291 (para enfermedades autoinmunes), SC262 (para malignidades B-celulares refractarias) y la plataforma fusógena. Se esperan datos clínicos de prueba de concepto en múltiples estudios en 2024 y 2025.
Sana Biotechnology (NASDAQ: SANA)는 1형 당뇨병 및 B 세포 매개 자가면역 질환에 집중하기 위한 전략적 전환을 발표했다. 이 회사는 종양학에서 SC291 및 SC379 신경아교세포 전구체 프로그램의 개발을 중단하고 이들 이니셔티브에 대한 파트너십을 모색할 것이다. 이 재구성은 2026년까지 현금 상태를 연장하나, 2024년 운영 현금 소모는 이전의 2억 달러 가이던스를 초과할 수 있다.
회사는 UP421(비타민 HIP으로 수정된 이자 세포), SC291(자가면역 질환용), SC262(내성 B 세포 악성종양용) 및 융합 플랫폼의 개발을 우선시할 것이다. 임상 개념 증명 데이터는 2024년과 2025년 동안 여러 연구에서 기대된다.
Sana Biotechnology (NASDAQ: SANA) a annoncé un changement stratégique pour se concentrer sur le diabète de type 1 et les maladies auto-immunes médiées par les cellules B. L'entreprise suspendra le développement de SC291 en oncologie et du programme de cellules progénitrices gliales SC379, recherchant des partenariats pour ces initiatives. La restructuration prolongera la disponibilité de liquidités jusqu'en 2026, bien que la consommation de liquidités d'exploitation en 2024 pourrait dépasser l'estimation précédente de 200 millions de dollars.
L'entreprise donnera la priorité au développement de UP421 (cellules d'îlots modifiées par HIP), SC291 (pour les maladies auto-immunes), SC262 (pour les malignités B-cellulaires réfractaires) et à la plateforme fusogène. Des données cliniques de preuve de concept sont attendues dans plusieurs études en 2024 et 2025.
Sana Biotechnology (NASDAQ: SANA) hat einen strategischen Wechsel angekündigt, um sich auf Typ-1-Diabetes und von B-Zellen vermittelte Autoimmunerkrankungen zu konzentrieren. Das Unternehmen wird die Entwicklung von SC291 in der Onkologie und das SC379-Programm für gliale Vorläuferzellen einstellen und Partnerschaften für diese Initiativen suchen. Die Umstrukturierung verlängert die finanzielle Laufzeit bis 2026, obgleich der operative Cashburn für 2024 die bisherigen Leitlinien von 200 Millionen Dollar überschreiten könnte.
Das Unternehmen wird die Entwicklung von UP421 (HIP-modifizierte Inselzellen), SC291 (für Autoimmunerkrankungen), SC262 (für refraktäre B-Zell-Malignome) und der Fusogen-Plattform priorisieren. Klinische Nachweis-Daten werden in mehreren Studien für 2024 und 2025 erwartet.
- Extended cash runway into 2026
- Multiple clinical data readouts expected in 2024-2025
- Strategic focus on high-potential therapeutic areas
- 2024 operating cash burn may exceed $200M guidance
- Suspension of oncology program SC291
- Workforce reduction announced
- Discontinuation of SC379 program
Insights
This strategic realignment represents a significant shift in Sana's development pipeline, with important implications for investors. The company is narrowing its focus to type 1 diabetes and B-cell mediated autoimmune diseases, while suspending oncology efforts for SC291 and the SC379 glial progenitor cell program.
The cash runway extension into 2026 is particularly noteworthy, though 2024 cash burn may exceed the previous
Early clinical data suggesting successful immune evasion with their hypoimmune platform (HIP) technology is promising, but investors should note this pipeline prioritization also reflects competitive pressures in the oncology space. The strategy to seek partnerships for deprioritized programs could potentially bring in additional capital or future milestone payments.
The market opportunity in type 1 diabetes and autoimmune diseases represents a strategic pivot toward less crowded therapeutic areas compared to oncology. The global type 1 diabetes market is projected to grow significantly, with high unmet needs for curative approaches versus current standard-of-care insulin therapy.
The company's decision to streamline operations while maintaining key value-driving programs demonstrates fiscal responsibility, though the workforce reduction signals near-term operational challenges. The multiple potential data readouts in 2024-2025 provide clear catalysts for potential value creation, which is important for a pre-revenue biotech company.
Investor focus should be on upcoming clinical results, particularly the ability of HIP-modified cells to demonstrate sustained immune evasion in humans - a key technical risk factor that could significantly impact the company's value proposition.
Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells
Modified strategy extends expected cash runway into 2026 with potential for multiple data readouts in 2024 and 2025
SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced it will prioritize future development activity for SC291, the company’s CD19-directed allogeneic CAR T cell therapy, in B-cell mediated autoimmune diseases (AID). The company will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs. Sana will increase its investment in its type 1 diabetes program with the cash savings from these changes.
“Early clinical data with our hypoimmune platform (HIP) suggest HIP-modified cells evade immune detection, giving us confidence in the potential of the platform across multiple therapeutic areas. At the same time, we need to ensure that we are directing our investments into the areas where we believe we can have the greatest impact for patients,” said Steve Harr, Sana’s President and Chief Executive Officer. “Greater focus on type 1 diabetes, SC291 in AID, and SC262 in refractory blood cancers will enhance our ability to present robust clinical data over the next twelve to eighteen months. This modified strategy will also help us reduce our cash burn but comes with the necessity of parting with some talented and valued colleagues. We thank them for their contributions toward building Sana and thank the patients who have been treated in the SC291 oncology study.”
With these changes, Sana extends its expected cash runway into 2026. Payments related to ongoing activities combined with the reduction in force may increase the 2024 operating cash burn above prior guidance of less than
“Since joining Sana, I have actively engaged with the team to understand both Sana and competitor data and believe it is the right time to prioritize where we believe we have the most differentiated therapeutic candidates and the highest probability of success for patients,” said Dhaval Patel, M.D., Ph.D., Chief Scientific Officer of Sana. “Type 1 diabetes is a significant unmet need, and we are optimistic that our program is novel and has the potential to offer patients meaningful benefit. The decision to prioritize SC291 in B-cell mediated autoimmune diseases is based on early clinical data with this drug in both oncology and autoimmune diseases, which show that therapy with SC291 can predictably lead to the deep B cell depletion that appears to drive an immune “reset” and significant clinical benefit in patients with B-cell mediated autoimmune diseases such as lupus. We look forward to generating and sharing more data from across our portfolio.”
Select Program Review
UP421 (HIP-modified primary pancreatic islet cells) in type 1 diabetes: The investigator-sponsored trial exploring the potential of HIP modifications to allogeneic primary islet cells to enable immune evasion and overcome transplant rejection in type 1 diabetes is active; Sana expects to share proof of concept data in 2024 and/or 2025.
SC291 (HIP-modified CD19-directed allogeneic CAR T) in autoimmune diseases: Sana continues enrollment in the Phase 1 GLEAM trial for SC291 for the treatment of B-cell mediated autoimmune diseases and expects to share clinical data in 2024 and/or 2025.
SC262 (HIP-modified CD22-directed allogeneic CAR T) in oncology: Sana continues enrollment in the Phase 1 VIVID study for patients with refractory B-cell malignancies who have failed a previous CD19-directed CAR T therapy and expects to share data in 2025.
SC451 (HIP-modified stem cell-derived pancreatic islet cells) in type 1 diabetes: Sana continues preclinical development of this HIP-modified, stem-cell derived therapy for patients with type 1 diabetes.
SG299 (in vivo CAR T with CD8-targeted fusogen delivery of a CD19-directed CAR): Sana is continuing its preclinical development of this program, with potential in both B-cell mediated autoimmune diseases and oncology.
SC291 (HIP-modified CD19-directed allogeneic CAR T) in oncology: Given alternative opportunities within its pipeline as well as increased competition within blood cancers and uncertainty about the best path to regulatory and commercial success, Sana is halting enrollment and further internal investment in the Phase 1 ARDENT trial. It is actively seeking a licensing partner to support advancement.
SC379 (stem-cell derived glial progenitor cells) in various CNS diseases: Sana will actively seek a partner or opportunity to spin out this program into a new company.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, Bothell, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; expectations regarding the impact of the Company’s modified strategy on its cash burn and cash runway and its potential ability to present clinical data for the type 1 diabetes program, SC291 program in AID and SC262 program over the next twelve to eighteen months; expectations regarding how the Company will use the cash savings from the changes to its business; the potential ability of HIP-modified cells to evade immune detection; the potential of the HIP platform across a number of therapeutic areas; expectations regarding the Company’s cash runway; expectations regarding the Company’s 2024 operating cash burn; expectations regarding where the Company has the most differentiated therapeutic candidates and the highest probability of success; expectations regarding the type 1 diabetes program and its ability to offer patients meaningful benefits; the ability of deep B cell depletion to drive an immune “reset” and clinically benefit patients with B-cell mediated autoimmune diseases such as lupus; the Company’s expectations regarding the timing, substance, and impact of the data from its clinical trials as well as the investigator sponsored trial exploring HIP-modified primarily islet cells in patients with type 1 diabetes; and the Company’s future plans for the SC291 oncology and SC379 programs, including its ability to partner the SC291 oncology program or partner or spin out the SC379 program into a new company. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-Q dated August 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
What therapeutic areas will Sana Biotechnology (SANA) focus on after the November 2024 restructuring?
When will Sana Biotechnology (SANA) release clinical data for its type 1 diabetes program?
Which programs did Sana Biotechnology (SANA) suspend in November 2024?